First Consultations Held On WHO Pandemic Flu Framework Options 10/11/2017 Catherine Saez The World Health Organization is consulting member states and stakeholders on the future of its mechanism to help prepare the world for the next influenza pandemic. It is particularly asking whether countries should submit not only the biological samples of their influenza viruses, but also their genetic information through the mechanism. Also in question is whether the mechanism should be extended to cover seasonal influenza. Stakeholders had different views but all questioned the absence of recognition by the WHO of a widely used database currently hosting most of the world’s influenza genetic information. Continue reading -> WIPO Vaccines Report Contestable, With UN High-Level Panel Misquoted, Advocate Says 10/11/2017 Catherine Saez The World Intellectual Property Organization this week held an event that delved into research, markets and access for vaccines with panels that showed unusual breadth of representation for the UN IP agency. But health advocates have taken issue with the wording of a report released by WIPO at the event. Continue reading -> WIPO Hosts Widely Represented Discussion On Vaccine Innovation And Access 09/11/2017 Catherine Saez A well-represented set of experts this week held discussions on the current situation of access to vaccines, the market, the role of pharmaceutical companies, and partnerships. Vaccines were not a field much affected by patents in the past, but the situation has changed and new vaccines are now covered by intellectual property, which might constitute a barrier to access, according to speakers. Continue reading -> WHO Issues Guidelines Against Antibiotic Overuse In Farms And Food Industry 07/11/2017 Catherine Saez Against the growing threat of a world where bacteria can kill again because they have developed resistance to available antibiotics, and the lack of new promising options in the research pipeline, several international agencies are seeking solutions. The World Health Organization today published a set of recommendations to help stop the routine use of antibiotics to promote growth and prevent disease in healthy animals. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug 31/10/2017 Catherine Saez Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, dropping prices dramatically. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> WHO Draft 5-Year Plan Would Focus On Impact & Innovation, Be Discreet On Medicines Access 25/10/2017 Catherine Saez After the new head of the World Health Organization provided his vision for his tenure of the global health institution this summer, the organisation is working on its next programme of work for the period 2019-2023. A preliminary concept note has been issued for public consideration. The note lays out priorities and new orientations and describes a financially sober, more efficient organisation, focused on measurable impact, set on aligning with the United Nations Sustainable Development Goals, and affirming its role as a multi-stakeholder platform of global governance on health, but stays clear of controversial issues, such as the affordability of medicines. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WIPO Vaccines Report Contestable, With UN High-Level Panel Misquoted, Advocate Says 10/11/2017 Catherine Saez The World Intellectual Property Organization this week held an event that delved into research, markets and access for vaccines with panels that showed unusual breadth of representation for the UN IP agency. But health advocates have taken issue with the wording of a report released by WIPO at the event. Continue reading -> WIPO Hosts Widely Represented Discussion On Vaccine Innovation And Access 09/11/2017 Catherine Saez A well-represented set of experts this week held discussions on the current situation of access to vaccines, the market, the role of pharmaceutical companies, and partnerships. Vaccines were not a field much affected by patents in the past, but the situation has changed and new vaccines are now covered by intellectual property, which might constitute a barrier to access, according to speakers. Continue reading -> WHO Issues Guidelines Against Antibiotic Overuse In Farms And Food Industry 07/11/2017 Catherine Saez Against the growing threat of a world where bacteria can kill again because they have developed resistance to available antibiotics, and the lack of new promising options in the research pipeline, several international agencies are seeking solutions. The World Health Organization today published a set of recommendations to help stop the routine use of antibiotics to promote growth and prevent disease in healthy animals. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug 31/10/2017 Catherine Saez Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, dropping prices dramatically. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> WHO Draft 5-Year Plan Would Focus On Impact & Innovation, Be Discreet On Medicines Access 25/10/2017 Catherine Saez After the new head of the World Health Organization provided his vision for his tenure of the global health institution this summer, the organisation is working on its next programme of work for the period 2019-2023. A preliminary concept note has been issued for public consideration. The note lays out priorities and new orientations and describes a financially sober, more efficient organisation, focused on measurable impact, set on aligning with the United Nations Sustainable Development Goals, and affirming its role as a multi-stakeholder platform of global governance on health, but stays clear of controversial issues, such as the affordability of medicines. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WIPO Hosts Widely Represented Discussion On Vaccine Innovation And Access 09/11/2017 Catherine Saez A well-represented set of experts this week held discussions on the current situation of access to vaccines, the market, the role of pharmaceutical companies, and partnerships. Vaccines were not a field much affected by patents in the past, but the situation has changed and new vaccines are now covered by intellectual property, which might constitute a barrier to access, according to speakers. Continue reading -> WHO Issues Guidelines Against Antibiotic Overuse In Farms And Food Industry 07/11/2017 Catherine Saez Against the growing threat of a world where bacteria can kill again because they have developed resistance to available antibiotics, and the lack of new promising options in the research pipeline, several international agencies are seeking solutions. The World Health Organization today published a set of recommendations to help stop the routine use of antibiotics to promote growth and prevent disease in healthy animals. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug 31/10/2017 Catherine Saez Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, dropping prices dramatically. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> WHO Draft 5-Year Plan Would Focus On Impact & Innovation, Be Discreet On Medicines Access 25/10/2017 Catherine Saez After the new head of the World Health Organization provided his vision for his tenure of the global health institution this summer, the organisation is working on its next programme of work for the period 2019-2023. A preliminary concept note has been issued for public consideration. The note lays out priorities and new orientations and describes a financially sober, more efficient organisation, focused on measurable impact, set on aligning with the United Nations Sustainable Development Goals, and affirming its role as a multi-stakeholder platform of global governance on health, but stays clear of controversial issues, such as the affordability of medicines. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Issues Guidelines Against Antibiotic Overuse In Farms And Food Industry 07/11/2017 Catherine Saez Against the growing threat of a world where bacteria can kill again because they have developed resistance to available antibiotics, and the lack of new promising options in the research pipeline, several international agencies are seeking solutions. The World Health Organization today published a set of recommendations to help stop the routine use of antibiotics to promote growth and prevent disease in healthy animals. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug 31/10/2017 Catherine Saez Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, dropping prices dramatically. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> WHO Draft 5-Year Plan Would Focus On Impact & Innovation, Be Discreet On Medicines Access 25/10/2017 Catherine Saez After the new head of the World Health Organization provided his vision for his tenure of the global health institution this summer, the organisation is working on its next programme of work for the period 2019-2023. A preliminary concept note has been issued for public consideration. The note lays out priorities and new orientations and describes a financially sober, more efficient organisation, focused on measurable impact, set on aligning with the United Nations Sustainable Development Goals, and affirming its role as a multi-stakeholder platform of global governance on health, but stays clear of controversial issues, such as the affordability of medicines. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug 31/10/2017 Catherine Saez Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, dropping prices dramatically. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> WHO Draft 5-Year Plan Would Focus On Impact & Innovation, Be Discreet On Medicines Access 25/10/2017 Catherine Saez After the new head of the World Health Organization provided his vision for his tenure of the global health institution this summer, the organisation is working on its next programme of work for the period 2019-2023. A preliminary concept note has been issued for public consideration. The note lays out priorities and new orientations and describes a financially sober, more efficient organisation, focused on measurable impact, set on aligning with the United Nations Sustainable Development Goals, and affirming its role as a multi-stakeholder platform of global governance on health, but stays clear of controversial issues, such as the affordability of medicines. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug 31/10/2017 Catherine Saez Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, dropping prices dramatically. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> WHO Draft 5-Year Plan Would Focus On Impact & Innovation, Be Discreet On Medicines Access 25/10/2017 Catherine Saez After the new head of the World Health Organization provided his vision for his tenure of the global health institution this summer, the organisation is working on its next programme of work for the period 2019-2023. A preliminary concept note has been issued for public consideration. The note lays out priorities and new orientations and describes a financially sober, more efficient organisation, focused on measurable impact, set on aligning with the United Nations Sustainable Development Goals, and affirming its role as a multi-stakeholder platform of global governance on health, but stays clear of controversial issues, such as the affordability of medicines. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> WHO Draft 5-Year Plan Would Focus On Impact & Innovation, Be Discreet On Medicines Access 25/10/2017 Catherine Saez After the new head of the World Health Organization provided his vision for his tenure of the global health institution this summer, the organisation is working on its next programme of work for the period 2019-2023. A preliminary concept note has been issued for public consideration. The note lays out priorities and new orientations and describes a financially sober, more efficient organisation, focused on measurable impact, set on aligning with the United Nations Sustainable Development Goals, and affirming its role as a multi-stakeholder platform of global governance on health, but stays clear of controversial issues, such as the affordability of medicines. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> WHO Draft 5-Year Plan Would Focus On Impact & Innovation, Be Discreet On Medicines Access 25/10/2017 Catherine Saez After the new head of the World Health Organization provided his vision for his tenure of the global health institution this summer, the organisation is working on its next programme of work for the period 2019-2023. A preliminary concept note has been issued for public consideration. The note lays out priorities and new orientations and describes a financially sober, more efficient organisation, focused on measurable impact, set on aligning with the United Nations Sustainable Development Goals, and affirming its role as a multi-stakeholder platform of global governance on health, but stays clear of controversial issues, such as the affordability of medicines. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Draft 5-Year Plan Would Focus On Impact & Innovation, Be Discreet On Medicines Access 25/10/2017 Catherine Saez After the new head of the World Health Organization provided his vision for his tenure of the global health institution this summer, the organisation is working on its next programme of work for the period 2019-2023. A preliminary concept note has been issued for public consideration. The note lays out priorities and new orientations and describes a financially sober, more efficient organisation, focused on measurable impact, set on aligning with the United Nations Sustainable Development Goals, and affirming its role as a multi-stakeholder platform of global governance on health, but stays clear of controversial issues, such as the affordability of medicines. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts